re: spp extended...joke!!
t4p, fully agree with what you're saying about a JV etc being the key. But I think the company might be further along with negatiations than the market realises.
From the Dec 20 announcement:
"A leading International pathology company has agreed to participate in a blind study to validate the accuracy of the Genechip and compare it to current detection methods. The trial will involve over 500 clinical sputum samples from patients with lung disease"
and
"We have also stated that partnering is a key strategy that we will use to gain market access and we have been extremely active in this area in the last few months”
So who is the international pathology company they're already working with? And how have they been extremely active partnering?
BPH Price at posting:
0.0¢ Sentiment: None Disclosure: Held
